Please email the editors at 'theniche at nature.com' to propose new posts.

Main

Archive by category: Blood stem cells

Bookmark in Connotea

Hematopoiesis, no hedgehog needed

While covering a couple papers just out in Cell Stem Cell, reporter Simone Alves uncovered an interesting conversation about how the genetic constructs used to explore a protein's role can affect results: This will be on the main site next week, but I thought I'd post it here for now.

Besides illuminating basic biology, a better handle on how the blood supply is replenished could reveal ways to treat blood cancers and other diseases. Hedgehog signalling, vital in normal development, was thought to play an important role in haematopoiesis, but two papers published recently in Cell Stem Cell question whether this is really the case.

Iannis Aifantis and his team at New York University investigated a conditional knockout mouse in which the hedgehog (Hh) effector, a protein called Smoothened (Smo), is deleted in adult mice1. In this model, deletion was triggered by chemically inducing expression of interferon-alpha. To their surprise, they detected no difference between the knockouts and controls when they measured haematopoiesis, peripheral blood count and colony formation in blood samples in vitro. The cells could also compete with wild-type cells when transplanted into nude mice, and overexpressing the protein didn't expand the haematopoietic stem cell (HSC) numbers or abilities.

"This was a big surprise", says Aifantis, revealing that he had the whole set of experiments repeated just to be sure of the results. Gary Gilliland's team at Harvard University in Boston reported similar findings in the same mouse knockout model, confirming that Hh does indeed appear to be dispensable for haematopoiesis2.

Interestingly, these two studies contradict a lot of the published literature, which suggests a role for Hh signalling in HSC regulation. "Not only did we not prove this, we actually disproved it," Aifantis continues. "It took a long time, but we knew we had something interesting."

"This is surprising because previous work using both gain- and loss-of-function approaches has suggested a critical role for Hh in the development of haematopoietic cells,” says Tannishtha Reya of Duke University in Durham, North Carolina. “It's scientifically important to examine every aspect; we need to look at all the experiments in an integrated way." Earlier this year, Reya's lab showed, in a different mouse model in which Smo was deleted at an earlier stage, that blocking Hh signalling reduced the regenerative capacity of HSC. So why the difference?

In Reya's opinion, it comes down to three things: timing, context, and the method of deletion. Both Reya and Aifantis believe that because the vav-Cre model that Reya's lab used is active from embryonic stages, the timing of the deletion could be the key. Early deletion may prevent other pathways from compensating and thus may reveal defects more readily. In terms of context, the mouse model used by Gilliland and Aifantis requires interferon expression, which has been reported to activate HSCs, explains Reya. (Aifantis believes the effect of interferon is negligible.) Other differences could be due to whether the gene is deleted in germline, giving rise to animals that lack the gene entirely, or if the gene is deleted conditionally, using techniques that apply only in certain tissues or under certain circumstances.

Particularly interesting was that Aifantis's paper showed that the Smo knockout had no effect on T cell development, yet an earlier paper from his lab using a different mouse system had the opposite result. In addition, a recent germline deletion of Smo studied by yet another lab also caused a defect in T cell development3. "This was the biggest surprise", said Aifantis, because it further questions the importance of the backgrounds of the mice.

There are certainly clinical implications for these studies, agree Aifantis and Reya. Most studies, including these, demonstrate that loss of Hh signaling allows haematopoietic cells to retain at least some functional capacity. This suggests that the use of small molecule inhibitors of Smo may be valuable in the treatment of leukaemias, in which Hh plays a role, because they will be able to kill cancer cells without severely affecting normal stem cells.

These papers certainly leave a lot of questions unanswered. It will be important to look at early haematopoiesis and use alternative mouse models to gain a fuller picture of what is really going on, says Reya. Aifantis agrees, adding that "we may be looking for answers before we know if they even exist".

Related articles
Self-renewing blood and leukaemia cells need hedgehog

References
1. Gao, J. et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 4, 548–558 (2009).
2. Hofmann, I. et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 4, 559–567 (2009).
3. Dierks, C. et al. Expansion of Bcl-Abl leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell 14, 238–249 (2008).

Author affiliation
Simone Alves is a freelance writer based in London.

Bookmark in Connotea

Beating heart triggers blood stem cells in the embryo

Here's a highlight for research published in Cell and Nature:

Beating heart triggers blood stem cells in the embryo

Embryonic haematopoiesis needs flow, nitric oxide signalling

Blood stem cells are born just outside the embryonic heart. Though this fact is well known, the reasons behind it have posed a persistent mystery. Now two strands of research, one starting with embryonic stem cells, another with zebrafish, provide big clues. The solution may help researchers create a useful but elusive cell — the haematopoietic stem cells capable of replenishing an entire blood system.

The work, led by two teams of researchers from Harvard University, shows that haematopoietic stem cells form best under stress — more specifically, under the strain exerted by moving fluid, the flow created by a beating heart.

Continue reading "Beating heart triggers blood stem cells in the embryo" »

Bookmark in Connotea

Around the web: some stem cell synopses

Why do I seem to be working harder and harder, but covering less and less? The vast majority of my readers, I’m sure, found the answer long before I did. In the eighteen months since Nature Reports Stem Cells has gone live, stem-cell happening have increased appreciably, inexorably, exhaustingly.

With so much content, we need filters more than ever, and on the cancer stem cell front, I just want to give a big thank-you to Alex Bersenev for his post over on Hematopoiesis, who summarized, organized, and emphasized important threads of my and others’ reporting on cancer stem cells. Another nice collection (including links to some open-access reviews) is on Jim Till’s cancer stem cell blog.

Also, and I meant to put this up long, long ago, his coverage of the ASH meeting focuses on aging and cancer. Check that out here.

Bookmark in Connotea

Cancer stem cells: controversies and misconceptions

Nature recently published a paper by Sean Morrison and others finding that melanoma stem cells are not rare and that standard assays to identify tumorigenic cells fail to detect a large portion of them. This prompted two letters describing an earlier study by David Taussig and others which found that the antibodies used to detect the leukemogenic cells first identified by John Dick changed their behaviour. Another letter pointed out the role that the extracellular matrix plays in shielding transplanted cells from the immune response, and suggested that this could provide insight in developing immune-based therapies to cancer.

Here, we publish that correspondence along with replies from David Taussig, which describes evidence for that cancer stem cell hypothesis, including his own evidence that leukemia-initiating cells are less than 1 in 100 cells. Finally, a reply by John Dick and colleagues says that the effects described by Taussig do not apply to a key leukemogenic cell marker and goes on to describe misconceptions about the cancer stem cell model.

Read those letters below. Here are links to NPG's research and other articles on cancer stem cells.

Continue reading "Cancer stem cells: controversies and misconceptions" »

Bookmark in Connotea

Blood-forming and esophageal stem cells: find, see, manipulate

Blood-forming stem cells have recently garnered some attention. Genzyme’s drug to boost circulating stem cells in patients with blood cancers won FDA approval on Monday. Here is Genzyme’s description of its small molecule chemokine receptor antagonist. Also, two research teams from Stanford have found ways to make artificial versions of the microenvironments where blood forms (See below), and a third team from Germany and Switzerland describes away to track individual blood-forming stem cells .

But it's not all bloody. Esophageal stem cells made the cover of the Journal of Clinical investigation. The cells lining your throat strike an “exquisite equilibrium between proliferation and differentiation.” Researchers led by Anil Rustgi at the University of Pennsylvania, used DNA-labeling to identify a population of slow-cycling, apparently self-renewing cells in the esophagus. Then they studied these cells in three-dimensional culture and found that they grew into esophageal structures. When these cells were placed in immunodeficient mice, they formed epithelial structures, and when they were placed in a mouse model of esophageal reflux disease, they migrated to the site of injury. Here’s the press release.

Continue reading "Blood-forming and esophageal stem cells: find, see, manipulate" »

Bookmark in Connotea

Umbilical Cord Blood Companies in Asia

This week, announcements of deals to bank and use umbilical cord blood in China, India, Vietnam and South Korea point to an industry that is both promising and prone to overpromising. Companies trying to attract self-paying patients often conflate established therapies with highly experimental and unproven procedures.

Cord blood banking is already an established business. Today, BioSpectrumAsia reported a joint venture between Apollo Therapeutics and Cadila Pharmaceuticals in India and the well-known cord blood company StemCyte.

Established uses cord blood include blood disorders, bone-marrow failure, and genetic metabolism disorders. Many researchers are trying to figure out just what these cells are capable of. Saudi Arabia is heavily investing in blood-derived stem cells and banks geared at treating the population in the Middle East. ( See our article ). The Chinese government has also announced plans to open two more umbilical cord blood banks for non-kin transplants.

In a policy statement that’s full of information, the American Academy of Pediatrics discourages private cord blood banking and warns against unsubstantiated claims. “Cord blood donation should be discouraged when cord blood stored in a bank is to be directed for later personal or family use, because most conditions that might be helped by cord blood stem cells already exist in the infant’s cord blood (ie, premalignant changes in stem cells).”

This is the kind of private cord blood service that will soon be offered in Vietnam. Vietnamnet reports that a Singapore company, CordLabs, agreed to transfer technology to a Vietnamese company, Mekophar. Beginning some time next quarter, parents can, for $2000, deposit umbilical cords and umbilical membranes of their children for 25 years. According to an earlier article, the company intends to establish four stem cell banks in Vietnam. The articles indicate that the project also includes public banking and charity services, plus Vietnam’s desire to foster this kind of research. The articles did not specify what promises were being made to parents.

A merger of an umbilical cord stem-cell company with a stem-cell company reveals the broadest and most unsubstantiated claims. South Korea-based Histostem plans to merge with the Florida company, Stem Cell Therapy International.

Though StemCyte can be accused of overstating, the only disease that StemCyte mentions specifically on its homepage is the blood disorder thalassemia. Stem Cell Therapy’s website, in contrast, is full of promises. It boasts videos and personal accounts of patients receiving stem cell therapies for multiple sclerosis and stroke. Two “solutions” are the “rejuvenation of women during menopause” and “complex therapy of cosmetics problems.” Its website states, “A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others.” It does not say that the vast majority of current stem-cell treatments are for blood disorders or to supply functioning bone marrow. Nor does it say that stem-cell treatments for neurodegenerative disorders are, to say the least, far from established. A review on blood- and marrow-derived stem cell treatments in JAMA published Feb 27, 2008 by Burt and others found only 69 reports to assess, including several on multiple sclerosis. The editors’ summary was “Their analysis suggests that stem cells harvested from blood or bone marrow may provide modest disease-ameliorating effects in selected patients with some autoimmune diseases and some cardiovascular disorders.”

At the bottom of Stem Cell Therapy’s home page, are glowing adjectives: “approved” among them, but clicking on that word does not tell me what entity approved the therapies. Here’s how the head of the Korean Histostem, Han Hoon, describes the strategy in a press release issued by the two companies. “We intend to take the research data that the Korean FDA already approved and submit it to the U.S. FDA, with the objective of getting the U.S. FDA approval in advance of other companies now researching umbilical stem cell treatments for a variety of different diseases." My understanding is that while the Korean FDA is supervising some trials with these cells, it has not approved any therapies.

There are organizations that are trying to ensure that promising results for potential therapeutic applications don’t transform into unsubstantiated claims. The Stem Cell Network of the Asian-Pacific Region ( SNAP ) has taken on the ambitious goal of helping people know where the science stands because, in the words of one of the founders, “There’s a lot of bad information out there.”


Bookmark in Connotea

Reader feedback: Blood and light, show more data

Alexey Bersenev has written in to warn for caution in extrapolating potential applications of a recent Nature paper that identified a mechanism linking circadian rhythms and the movement of blood stem cells into circulation.
You can read our summary here.

I don't think we can say "it may mean that more HSCs can be harvested from the bone marrow, by collecting at the right time of day" in terms of clinical application so far.
Because in bone marrow transplant clinic HSCs harvested after injection of drugs, mobilized of HSC (such as G-CSF). Authors didn't study how administration of this drug will affect circadian oscillations of HSCs. It's could be synergistic or could't.
It was pointed out in our blog:
http://hematopoiesis.info/2008/02/25/stem-cells-know-its-their-time-to-circulate

"The clinical implication of this study will be more convincing if it is shown that G-CSF or PTH treatment to increase HSC collection from the periphery will be enhanced if harvested at a certain time during the day"

Bookmark in Connotea

Research highlight: Blood stem cells move with daylight

Here's a summary by Jen Middleton of an article just out in Nature. We'll have it as an archived research highlight soon.
Blood stem cells move between circulating blood and bone marrow, but little is known about what controls the traffic between the two. Reporting in Nature, Paul Frenette and colleagues from the Mount Sinai School of Medicine in New York show that levels of circulating HSCs fluctuate with natural circadian rhythms.
The team originally set out to study how a common treatment administered to patients before bone marrow transplants stimulates haematopoietic stem cells (HSCs). Working in mice, they noted by chance that HSC traffic increased under continuous exposure to light.
Under standard conditions of 12 hours light – 12 hours dark, the number of circulating HSCs in mice fluctuated predictably. Yet keeping mice in continuous light, disrupted this fluctuation pattern. Similar irregularities were observed in ‘jet-lagged’ mice. The team then looked at expression of a blood-signalling molecule called CXCL12 known to regulate HSC migration in the bone marrow. Levels of this chemokine fluctuated with exactly opposite timing such that when levels dropped, HSCs were released. This rhythmic pattern of CXCL12 expression was also disrupted in animals kept in constant light.
The “flight or fight” response releases HSCs from bone marrow, and the researchers wondered whether the neurons controlling this might also influence the patterns. A series of experiments found that these neurons (the adrenergic neurons of the sympathetic nervous system) delivered signals to the bone marrow in a pattern correlated with circadian rhythms. These signals triggered HSCs to enter circulation. Disrupting a particular kind of receptor known as the 3-adrenergic receptor was sufficient to disrupt the HSC cycle. Intriguingly, the bone-secreting cells or osteoblasts generally considered an important source of CXCL12 lack these receptors, so the neurons must directly target a different cell type.
These findings provide further clues to understanding the bone marrow stem cell niche. In practical terms, it may mean that more HSCs can be harvested from the bone marrow, by collecting at the right time of day.
Mendez-Ferrer S et al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations. Nature doi:10.1038/nature06685 Advance online publication 6 February 2008